Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monash IVF GroupMNIVF 76 Debt-to-Equity is 0.78 as of Dec. 2025, which is 42% above its 10-year median of 0.55. GuruFocus rates MNIVF with a GF Score™ of 76/100 and a GF Value™ of $0.81. The stock has 7 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Monash IVF Group ranks worse than 76.5% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Monash IVF Group's Debt-to-Equity or its related term are showing as below:
MNIVF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16 Med: 0.55 Max: 0.78
Current: 0.78
During the past 12 years, the highest Debt-to-Equity Ratio of Monash IVF Group was 0.78. The lowest was 0.16. And the median was 0.55.
MNIVF's Debt-to-Equity is ranked worse than 76.5% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs MNIVF: 0.78
Monash IVF Group (OTCPK:MNIVF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Monash IVF Group Debt-to-Equity Related Terms
Monash IVF Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MNIVF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (MNIVF) has a Debt-to-Equity of 0.78 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Monash IVF Group and its competitors. This is 42% above median its historical median of 0.55. Over the past decade, Monash IVF Group's Debt-to-Equity has ranged from 0.16 to 0.78. According to the industry distribution chart, Monash IVF Group ranks #140 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 76.5%.
Is Monash IVF Group's Debt-to-Equity too high?
Monash IVF Group's current Debt-to-Equity of 0.78 is 42% above median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 0.78. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Monash IVF Group's value of 0.78 is 136.4% above this industry median. Based on the distribution chart, Monash IVF Group ranks #140 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Monash IVF Group has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #140 out of 183 companies for Debt-to-Equity. This places Monash IVF Group in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Monash IVF Group's value of 0.78 is 136.4% above this benchmark. Historically, Monash IVF Group's own Debt-to-Equity has ranged from 0.16 to 0.78 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 0.33, Monash IVF Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current Debt-to-Equity of 0.78 is 136.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current Debt-to-Equity is 0.78, which is 42% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current Debt-to-Equity of 0.78. The stock's GF Value™ is $0.81, compared to a current price of $0.40 — trading 50.6% below its estimated fair value. The current Debt-to-Equity is 0.78, which is 42% above median its 10-year median of 0.55 and 136.4% above the Medical Diagnostics & Research industry median of 0.33. Monash IVF Group's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current Debt-to-Equity is 0.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 50.6% below its estimated GF Value™ of $0.81.
Key valuation signals for MNIVF:
Debt-to-Equity: 0.78 (42% above median its 10-year median of 0.55)
GF Value™: $0.81 vs. price of $0.40 (50.6% below fair value)
Industry Position: 136.4% above the Medical Diagnostics & Research median (#140 of 183)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
76GF Score
Get the complete analysis for MNIVF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
